Drug Sponsors

Sorrento Therapeutics acquires rights to produce rIVIG

Wednesday, January 9, 2013 02:33 PM

Sorrento Therapeutics, a development-stage biopharmaceutical company, has acquired worldwide rights that will allow for the application of its antibody library technology for the production of recombinant Intravenous immunoglobulins (rIVIG).

More... »

Exela Pharma Sciences to create 38 jobs

Wednesday, January 9, 2013 11:11 AM

Exela Pharma Sciences, a pharmaceutical manufacturer and subsidiary of Exela PharmSci, will expand its facility in Lenoir, N.C.

More... »

Shire to acquire Lotus Tissue Repair

Wednesday, January 9, 2013 09:45 AM

Shire, a global specialty biopharmaceutical company, has signed an agreement to acquire Lotus Tissue Repair, a Cambridge, Mass.-based biotechnology company developing the first and only protein replacement therapy currently being investigated for the treatment of dystrophic epidermolysis bullosa (DEB).

More... »

Questcor Pharmaceuticals to acquire BioVectra

Monday, January 7, 2013 01:18 PM

Questcor Pharmaceuticals, a biopharmaceutical company based in Anaheim Hills, Calif., has signed a definitive agreement to acquire all issued and outstanding shares of BioVectra, a Canadian supplier of contract manufacturing services, for an upfront payment of $50 million.

More... »

Lilly reassumes sole worldwide rights for novel basal insulin analog

Monday, January 7, 2013 10:55 AM

Global pharmaceutical company Eli Lilly and Boehringer Ingelheim, a Germany-based pharmaceutical company, will adjust the scope of their diabetes alliance with respect to LY2605541, Lilly's investigational novel basal insulin analog, with Lilly reassuming sole worldwide development and commercialization rights to LY2605541.

More... »

Pepscan and U.S. company to discover novel antibodies

Monday, January 7, 2013 09:29 AM

Pepscan Therapeutics, a developer of protein mimicry technologies based in The Netherlands, has entered into a multi-target research agreement with an undisclosed U.S.-based antibody discovery company. 

More... »

Gradalis closes $24M Series B financing to advance FANG personalized cancer vaccine

Friday, January 4, 2013 12:26 PM

Gradalis, a privately-held, fully-integrated biotech based in Dallas, Texas, has closed a $24 million Series B round of financing.

More... »

Labrys Biologics secures $31M financing, acquires antibody for chronic migraine from Pfizer

Friday, January 4, 2013 11:57 AM

Labrys Biologics, a development stage biotechnology company focused on chronic migraines, has completed a $31 million Series A financing from four leading venture capital firms: venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures. With the close of the financing, Labrys has acquired RN-307 from Pfizer Inc., a phase II ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine. In addition, Steven P. James has been appointed president and CEO.

More... »

Government backs small business with $8.1M funding boost

Friday, January 4, 2013 11:01 AM

The U.K. government is holding two new competitions, with a total of up to $8.1 million in funding, for small businesses who have ideas that can improve the experience for older people at the end of their life or improve the experience for people with mental health illnesses.

More... »

Biogen Idec to discontinue development of ALS drug

Friday, January 4, 2013 10:29 AM

Weston, Mass.-based Biogen Idec has decided to discontinue development of dexpramipexole in amyotrophic lateral sclerosis (ALS), after top-line results of EMPOWER, its phase III trial, did not meet its primary endpoint, a joint rank analysis of function and survival, and no efficacy was seen in the individual components of function or survival.

More... »